A detailed history of Bluestein R H & CO LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Bluestein R H & CO LLC holds 6,227 shares of EXAS stock, worth $308,485. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,227
Previous 6,392 2.58%
Holding current value
$308,485
Previous $252,000 19.84%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$31.97 - $49.37 $5,275 - $8,146
-165 Reduced 2.58%
6,227 $202,000
Q2 2022

Aug 11, 2022

SELL
$35.61 - $76.23 $9,187 - $19,667
-258 Reduced 3.88%
6,392 $252,000
Q1 2022

May 11, 2022

BUY
$57.56 - $82.54 $122,890 - $176,222
2,135 Added 47.29%
6,650 $465,000
Q4 2021

Feb 14, 2022

SELL
$72.5 - $100.68 $215,687 - $299,523
-2,975 Reduced 39.72%
4,515 $351,000
Q3 2021

Nov 12, 2021

BUY
$90.24 - $124.05 $50,083 - $68,847
555 Added 8.0%
7,490 $715,000
Q2 2021

Aug 13, 2021

BUY
$93.66 - $139.27 $649,532 - $965,837
6,935 New
6,935 $862,000
Q3 2020

Nov 12, 2020

SELL
$72.92 - $102.01 $284,315 - $397,736
-3,899 Closed
0 $0
Q2 2020

Aug 12, 2020

SELL
$55.75 - $92.75 $3.22 Million - $5.36 Million
-57,812 Reduced 93.68%
3,899 $339,000
Q1 2020

May 12, 2020

BUY
$37.9 - $104.44 $2.23 Million - $6.14 Million
58,811 Added 2027.97%
61,711 $3.58 Million
Q4 2019

Feb 13, 2020

BUY
$77.66 - $99.74 $225,214 - $289,246
2,900 New
2,900 $268,000
Q3 2019

Nov 13, 2019

SELL
$90.37 - $122.49 $302,739 - $410,341
-3,350 Closed
0 $0
Q2 2019

Aug 12, 2019

BUY
$89.51 - $118.04 $299,858 - $395,434
3,350 New
3,350 $395,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.77B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Bluestein R H & CO LLC Portfolio

Follow Bluestein R H & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bluestein R H & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bluestein R H & CO LLC with notifications on news.